A HUNTER-based fitness study looking at the effects of interval training on children with cystic fibrosis is achieving some “outstanding” results, a local exercise physiologist says. Continue reading Pushing the envelope promising for patients
Because CF has so many moving parts, it is important to keep all medications and treatments organized.
To read Gunnar’s blog, please visit www.gunnaresiason.com. Continue reading Cystic Fibrosis Step by Step: Organizational Needs
By Amy Braid
As the summer draws to a close I prepare myself for the upcoming school year. This year my step-daughter starts high school. A new school and a new year.
Along with a new year comes new germs. New chances to get sick. Yuck!
Improved diagnosis and treatment has extended cystic fibrosis (CF) patients’ life expectancy into adulthood. Continue reading Cystic Fibrosis Patients Shouldn’t Skip Supplements
From Cystic Fibrosis News Today
A review study suggests that positive expiratory pressure (PEP) devices are more effective than other airway clearance approaches in reducing pulmonary exacerbations in patients Continue reading PEP Devices Can Help Reduce CF Pulmonary Flare-ups, Review Finds
Published originally in Cystic Fibrosis News Today
By Charles Moore
Nivalis Therapeutics, Inc., a Boulder, Colorado-based clinical stage pharmaceutical company, announced that the first patient has been dosed in the Phase 2 clinical trial of its lead investigational drug, N91115, a stabilizer Continue reading Cystic Fibrosis Phase 2 Trial of Drug Aiming to Stabilize Key CF Gene Underway
Just like some people talk too much and hang out with the wrong crowd, a mutant protein responsible for most cases of cystic fibrosis acts similarly, scientists at The Scripps Research Institute reported Monday.
The cystic fibrosis transmembrane conductance regulator protein is so busy Continue reading Scripps scientists find protein flaw in cystic fibrosis
Arch Biopartners Inc., a portfolio based biotechnology company focused on developing innovative technologies that make a significant clinical impact on patients, today announced that the U.S. Food and Drug Administration (FDA) has Continue reading Arch Biopartners Receives Orphan Drug Designation from FDA for AB569
Corbus Pharmaceuticals Holdings, Inc. CRBP, +4.60% (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced today that the first Continue reading Corbus Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of Resunab(TM) for Treatment of Cystic Fibrosis
Cystic fibrosis is the most common fatal genetic disorder affecting children and young adults in Canada. Researchers have yet to find a cure, but a team from McGill recently made a discovery that’s giving Continue reading McGill research team makes cystic fibrosis discovery | CTV Montreal News